Pathology of melanocytic lesions: New, controversial, and clinically important issues

Journal of Surgical Oncology

Volumn 86, Issue 4, 2004, Pages 200-211

  Scolyer, Richard A ^a   Thompson, John F ^a,b   Stretch, Jonathan R ^a,b   Sharma, Raghwa ^a,c   McCarthy, Stanley W ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b University of Sydney   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

Diagnosis; Melanoma; Nevus; Prognosis; Sentinel node

Indexed keywords

CANCER DIAGNOSIS; CELL TYPE; CLINICAL FEATURE; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MELANOMA; MINIMALLY INVASIVE SURGERY; MITOSIS RATE; NEVUS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENTINEL LYMPH NODE BIOPSY; SKIN BIOPSY; TUMOR CLASSIFICATION;

BIOPSY, FINE-NEEDLE; CELL DIVISION; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MELANOMA; MITOTIC INDEX; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE BIOPSY; SKIN; SKIN NEOPLASMS;

EID: 3042771501     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20083     Document Type: Review

References (88)

1. Balch CM, Soong SJ, Gershenwald JE, et al.: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-3634.
2. Azzola MF, Shaw HM, Thompson JF, et al.: Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: An analysis of 3,661 patients from a single center. Cancer 2003;97:1488-1498.
3. Francken AB, Shaw HM, Thompson JF, et al.: The prognostic importance of tumor mitotic rate confirmed in 1,317 patients with primary cutaneous melanoma and long-term follow-up. Ann Surg Oncol 2004;11:426-433.
4. Balch CM, Buzaid AC, Soong SJ, et al.: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-3648.
5. McGovern VJ, Cochran AJ, Van der Esch EP, et al.: The classification of malignant melanoma, its histological reporting and registration: A revision of the 1972 Sydney classification. Pathology 1986;18:12-21.
6. McGovern VJ, Mihm MC, Jr., Bailly C, et al.: The classification of malignant melanoma and its histologic reporting. Cancer 1973;32:1446-1457.
7. Ellis PS, Whitehead R: Mitosis counting-A need for reappraisal. Hum Pathol 1981;12:3-4.
8. Retsas S, Henry K, Mohammed MQ, et al.: Prognostic factors of cutaneous melanoma and a new staging system proposed by the American Joint Committee on Cancer (AJCC): Validation in a cohort of 1,284 patients. Eur J Cancer 2002;38:511-516.
9. Sabel MS, Taylor JM, Grover AC, et al.: Mitotic rate and younger age are predictors of sentinel lymph node positivity. Ann Surg Oncol 2003;10:S17.
10. Oliveira RS, Ferreira LM, Biasi LJ, et al.: Vertical growth phase and sentinel node in thin melanoma. Braz J Med Biol Res 2003;36:347-350.
11. Scolyer RA, Shaw HM, Thompson JF, et al.: Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. Am J Surg Pathol 2003;27:1571-1576.
12. Yu LL, Flotte TJ, Tanabe KK, et al.: Detection of microscopic melanoma metastases in sentinel lymph nodes. Cancer 1999;86:617-627.
13. Gershenwald JE, Colome MI, Lee JE, et al.: Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998;16:2253-2260.
14. Li LX, Crotty KA, McCarthy SW, et al.: A zonal comparison of MIB1-Ki67 immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol 2000;22:489-495.
15. Li LX, Crotty KA, Palmer AA, et al.: Argyrophilic staining of nucleolar organizer region count and morphometry in benign and malignant melanocytic lesions. Am J Dermatopathol 2003;25:190-197.
16. Li LX, Crotty KA, Palmer AA, et al.: Differentiating benign nevi from malignant melanoma using DNA microdensitometry and karyometry and maturation: A zonal comparison, correlation, and multivariate analysis. Anal Quant Cytol Histol 2002;24:234-243.
17. Li LX, Crotty KA, Scolyer RA, et al.: Use of multiple cytometric markers improves discrimination between benign and malignant melanocytic lesions: A study of DNA microdensitometry, karyometry, argyrophilic staining of nucleolar organizer regions and MIB1-Ki67 immunoreactivity. Melanoma Res 2003;13:581-586.
18. Bastian BC: Understanding the progression of melanocytic neoplasia using genomic analysis: From fields to cancer. Oncogene 2003;22:3081-3086.
19. Bastian BC, Kashani-Sabet M, Hamm H, et al.: Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res 2000;60:1968-1973.
20. Bastian BC, LeBoit PE, Pinkel D: Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am J Pathol 2000;157:967-972.
21. Bastian BC, Olshen AB, LeBoit PE, et al.: Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol 2003;163:1765-1770.
22. Bastian BC, Wesselmann U, Pinkel D, et al.: Molecular cytogenetic analysis of Spitz nevi shows clear differences to melanoma. J Invest Dermatol 1999;113:1065-1069.
23. Bastian BC, Xiong J, Frieden IJ, et al.: Genetic changes in neoplasms arising in congenital melanocytic nevi: Differences between nodular proliferations and melanomas. Am J Pathol 2002;161:1163-1169.
24. Clark WH, Jr., Elder DE, Guerry Dt, et al.: A study of tumor progression: The precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984;15:1147-1165.
25. Elder DE, Jucovy PM, Tuthill RJ, et al.: The classification of malignant melanoma. Am J Dermatopathol 1980;2:315-320.
26. Elder DE, Guerry Dt, Epstein MN, et al.: Invasive malignant melanomas lacking competence for metastasis. Am J Dermatopathol 1984;6:55-61.
27. Clark WH, Jr., Elder DE, Van Horn M: The biologic forms of malignant melanoma. Hum Pathol 1986;17:443-450.
28. Herlyn M, Thurin J, Balaban G, et al.: Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res 1985;45:5670-5676.
29. Clark WH, Jr., Elder DE, Guerry Dt, et al.: Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81:1893-1904.
30. Lefevre M, Vergier B, Balme B, et al.: Relevance of vertical growth pattern in thin level II cutaneous superficial spreading melanomas. Am J Surg Pathol 2003;27:717-724.
31. Cohen LM, McCall MW, Hodge SJ, et al.: Successful treatment of lentigo maligna and lentigo maligna melanoma with Mohs' micrographic surgery aided by rush permanent sections. Cancer 1994;73:2964-2970.
32. Zalla MJ, Lim KK, Dicaudo DJ, et al.: Mohs micrographic excision of melanoma using immunostains. Dermatol Surg 2000;26:771-784.
33. Morton DL, Wen DR, Wong JH, et al.: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-399.
34. Reintgen D, Cruse CW, Wells K, et al.: The orderly progression of melanoma nodal metastases. Ann Surg 1994;220:759-767.
35. Thompson JF, McCarthy WH, Bosch CM, et al.: Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 1995;5:255-260.
36. Thompson JF, Niewind P, Uren RF, et al.: Single-dose isotope injection for both preoperative lymphoscintigraphy and intraoperative sentinel lymph node identification in melanoma patients. Melanoma Res 1997;7:500-506.
37. Cascinelli N, Belli F, Santinami M, et al.: Sentinel lymph node biopsy in cutaneous melanoma: The WHO Melanoma Program experience. Ann Surg Oncol 2000;7:469-474.
38. Cochran AJ: Surgical pathology remains pivotal in the evaluation of 'sentinel' lymph nodes. Am J Surg Pathol 1999;23:1169-1172.
39. Messina JL, Glass LF, Cruse CW, et al.: Pathologic examination of the sentinel lymph node in malignant melanoma. Am J Surg Pathol 1999;23:686-690.
40. Starz H, Balda BR, Kramer KU, et al.: A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer 2001;91:2110-2121.
41. Li LX, Scolyer RA, Ka VS, et al.: Pathologic review of negative sentinel lymph nodes in melanoma patients with regional recurrence: A clinicopathologic study of 1,152 patients undergoing sentinel lymph node biopsy. Am J Surg Pathol 2003;27:1197-1202.
42. Cook MG, Green MA, Anderson B, et al.: The development of optimal pathological assessment of sentinel lymph nodes for melanoma. J Pathol 2003;200:314-319.
43. Dawson M, Doble P, Beavis A, et al.: Antimony by ICP-MS as a marker for sentinel lymph nodes in melanoma patients. Analyst 2003;128:217-219.
44. Scolyer RA, Thompson JF, Li L-XL, et al.: Antimony concentrations in nodal tissue can confirm sentinel node identity. Mod Pathol (in press).
45. Scolyer RA, Thompson JF, Li L-XL, et al.: Failure to remove "true" sentinel nodes can cause failure of the sentinel node biopsy technique. Evidence from antimony quantitation of false negative sentinel nodes from melanoma patients. Am Surg Oncol 2004;11:174S-177S.
46. Morton DL, Hoon DS, Cochran AJ, et al.: Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg 2003;238:538-549; discussion 549-550.
47. Perry MD, Seigler HF, Johnston WW: Diagnosis of metastatic malignant melanoma by fine needle aspiration biopsy: A clinical and pathologic correlation of 298 cases. J Natl Cancer Inst 1986;77:1013-1021.
48. Crotty KA, Scolyer RA, Li L, et al.: Spitz nevus versus Spitzoid melanoma: When and how can they be distinguished? Pathology 2002;34:6-12.
49. Scolyer RA, Crotty KA, Palmer AA, et al.: Pagetoid spread of melanocytes in Spitz naevi (authors reply). Pathology 2002;34:591.
50. Kornberg R, Ackerman AB: Pseudomelanoma: Recurrent melanocytic nevus following partial surgical removal. Arch Dermatol 1975;111:1588-1590.
51. Suster S: Pseudomelanoma. A pathologist's perspective. Int J Dermatol 1986;25:506-507.
52. Dymock RB, Menz J: Recurrent melanocytic naevi following partial removal (pseudomelanoma). Australas J Dermatol 1986;27:67-69.
53. Harvell JD, Bastian BC, LeBoit PE: Persistent (recurrent) Spitz nevi: A histopathologic, immunohistochemical, and molecular pathologic study of 22 cases. Am J Surg Pathol 2002;26:654-661.
54. Troxel DB: Pitfalls in the diagnosis of malignant melanoma: Findings of a risk management panel study. Am J Surg Pathol 2003;27:1278-1283.
55. Sanchez JL, Figueroa LD, Rodriguez E: Behavior of melanocytic nevi during pregnancy. Am J Dermatopathol 1984;6:89-91.
56. Lee HJ, Ha SJ, Lee SJ, et al.: Melanocytic nevus with pregnancy-related changes in size accompanied by apoptosis of nevus cells: A case report. J Am Acad Dermatol 2000;42:936-938.
57. Busam KJ: Metastatic melanoma to the skin simulating blue nevus. Am J Surg Pathol 1999;23:276-282.
58. Cooper PH: Deep penetrating (plexiform spindle cell) nevus. A frequent participant in combined nevus. J Cutan Pathol 1992;19:172-180.
59. Mehregan DA, Mehregan AH: Deep penetrating nevus. Arch Dermatol 1993;129:328-331.
60. Jin ZH, Kumakiri M, Ishida H, et al.: A case of combined nevus: Compound nevus and spindle cell Spitz nevus. J Dermatol 2000;27:233-237.
61. Mooi WJ: Histopathology of Spitz naevi and "Spitzoid" melanomas. Curr Top Pathol 2001;94:65-77.
62. Barnhill RL, Argenyi ZB, From L, et al.: Atypical Spitz nevi/tumors: Lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol 1999;30:513-520.
63. Wechsler J, Bastuji-Garin S, Spatz A, et al.: Reliability of the histopathologic diagnosis of malignant melanoma in childhood. Arch Dermatol 2002;138:625-628.
64. Llewellyn K, Barnhill RL: Distinguishing Spitz tumors from malignant melanoma: Potential role of comparative genomic hybridization and fluorescence in situ hybridization in diagnosis and prognosis. Adv Anat Pathol 2001;8:249-254.
65. Su LD, Fullen DR, Sondak VK, et al.: Sentinel lymph node biopsy for patients with problematic spitzoid melanocytic lesions: A report on 18 patients. Cancer 2003;97:499-507.
66. Lohmann CM, Coit DG, Brady MS, et al.: Sentinel lymph node biopsy in patients with diagnostically controversial spitzoid melanocytic tumors. Am J Surg Pathol 2002;26:47-55.
67. Conley J, Lattes R, Orr W: Desmoplastic malignant melanoma (a rare variant of spindle cell melanoma). Cancer 1971;28:914-936.
68. Quinn MJ, Crotty KA, Thompson JF, et al.: Desmoplastic and desmoplastic neurotropic melanoma: Experience with 280 patients. Cancer 1998;83:1128-1135.
69. Jain S, Allen PW: Desmoplastic malignant melanoma and its variants. A study of 45 cases. Am J Surg Pathol 1989;13:358-373.
70. Reed RJ, Leonard DD: Neurotropic melanoma. A variant of desmoplastic melanoma. Am J Surg Pathol 1979;3:301-311.
71. Ballo MT, Ang KK: Radiotherapy for cutaneous malignant melanoma: Rationale and indications. Oncology (Huntingt) 2004;18:99-107; discussion 107-110, 113-114.
72. McCarthy SW: Recent progress in malignant melanomas. Case 9: "Animal-type" or "melanophagic" naevi, the 23rd International Congress of the International Academy of Pathology, Nagoya, Japan, 2000.
73. Scolyer RA: Heavily pigmented melanocytic lesions. Are they all malignant? 23rd Annual Conference of the Australasian Society of Dermatopathology, Sydney, Australia, 2002.
74. Zembowicz A, Carney JA, Mihm MC: Pigmented epithelioid melanocytoma: A low-grade melanocytic tumor with metastatic potential indistinguishable from animal-type melanoma and epithelioid blue nevus. Am J Surg Pathol 2004;28:31-40.
75. Scolyer RA, Thompson JF, Warnke K, et al.: Pigmented epithelioid melanocytoma. Am J Surg Pathol (letter) (in press).
76. Carney JA, Ferreiro JA: The epithelioid blue nevus. A multi-centric familial tumor with important associations, including cardiac myxoma and psammomatous melanotic schwannoma. Am J Surg Pathol 1996;20:259-272.
77. Crowson AN, Magro CM, Mihm MC, Jr.: Malignant melanoma with prominent pigment synthesis: "animal type" melanoma-A clinical and histological study of six cases with a consideration of other melanocytic neoplasms with prominent pigment synthesis. Hum Pathol 1999;30:543-550.
78. Requena L, de la Cruz A, Moreno C, et al.: Animal type melanoma: A report of a case with balloon-cell change and sentinel lymph node metastasis. Am J Dermatopathol 2001;23:341-346.
79. Joseph E, Brobeil A, Glass F, et al.: Results of complete lymph node dissection in 83 melanoma patients with positive sentinel nodes. Ann Surg Oncol 1998;5:119-125.
80. Salti GI, Das Gupta TK: Predicting residual lymph node basin disease in melanoma patients with sentinel lymph node metastases. Am J Surg 2003;186:98-101.
81. Wagner JD, Davidson D, Coleman JJ III, et al.: Lymph node tumor volumes in patients undergoing sentinel lymph node biopsy for cutaneous melanoma. Ann Surg Oncol 1999;6:398-404.
82. Scolyer RA, Li L-XL, McCarthy SW, et al.: Micromorphometric features of positive sentinel nodes predict involvement if non-sentinel nodes in melanoma patients. Am J Clin Pathol (in press).
83. Cochran AJ, Wen DR, Huang R-R, et al.: Prediction of metastatic melanoma in non-sentinel nodes and clinical outcome based on the primary melanoma and the sentinel node (in press).
84. Lugassy C, Barnhill RL, Christensen L: Melanoma and extravascular migratory metastasis. J Cutan Pathol 2000;27:481.
85. Lugassy C, Haroun RI, Brem H, et al.: Pericytic-like angiotropism of glioma and melanoma cells. Am J Dermatopathol 2002;24:473-478.
86. Lugassy C, Kleinman HK, Fernandez PM, et al.: Human melanoma cell migration along capillary-like structures in vitro: A new dynamic model for studying extravascular migratory metastasis. J Invest Dermatol 2002;119:703-704.
87. Barnhill RL: The biology of melanoma micrometastases. Recent Results Cancer Res 2001;158:3-13.
88. Barnhill R, Dy K, Lugassy C: Angiotropism in cutaneous melanoma: A prognostic factor strongly predicting risk for metastasis. J Invest Dermatol 2002;119:705-706.